InVivo prices offering


Shares of InVivo Therapeutics (NVIV -34.9%) are down on heavy volume as traders react to its offering of 12.175M shares of common stock at $1.15, a 34% discount to yesterday's close of $1.75. The offering includes warrants priced at $0.00001 to purchase 6,087,500 shares at $1.4375. Underwriters over-allotment is 1,862,250 shares plus warrants to purchase up to 913,250 more. Closing date is May 9.

Gross proceeds will be ~$14M.

Comments (6)
  • Hoang6
    , contributor
    Comments (358) | Send Message
     
    Classic pump and dump!
    6 May 2014, 10:26 AM Reply Like
  • Patent News
    , contributor
    Comments (1464) | Send Message
     
    scamming shareholders
    6 May 2014, 10:38 AM Reply Like
  • ControlledRisk
    , contributor
    Comments (343) | Send Message
     
    Wow, I love how people ignore the fact it takes money to run a company.
    6 May 2014, 02:37 PM Reply Like
  • Grant Payne
    , contributor
    Comments (337) | Send Message
     
    Obviously, but this company hasn't done a single thing in 5+ years except make a dubious movie with monkeys in it. People should steer clear of this sham of a biotech.
    7 May 2014, 12:13 AM Reply Like
  • ControlledRisk
    , contributor
    Comments (343) | Send Message
     
    It has been a long road, but the trial is starting. Business wise, it makes a lot of sense to get money now before results. There are too many risks to waiting, no matter how confident you are. Obviously, that means investing is also risky. Calling it a sham is a little much. Even if the scaffold doesn't work, certainly that is not for lack of trying. The timeline is real now, there will be results in the next few months.
    7 May 2014, 02:30 PM Reply Like
  • Grant Payne
    , contributor
    Comments (337) | Send Message
     
    But they have had money and opportunity to begin clinical trials this whole time. They should have raised capital when their stock was around $4 a year ago, and their scaffold idea isn't all that amazing when you think about how all it really does is reduce inflammation.

     

    I could be wrong, maybe they'll be a miracle for spinal trauma, and that'd be great. I'm jaded on them, though. I didn't even lose money, I just grew tired.
    8 May 2014, 02:18 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs